# mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer

> **NCT03196986** · PHASE3 · COMPLETED · sponsor: **Beijing Mabworks Biotech Co., Ltd.** · enrollment: 517 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** mil60
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT03196986
- **Lead sponsor:** Beijing Mabworks Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-15
- **Primary completion:** 2019-08-01
- **Final completion:** 2021-07-30
- **Target enrollment:** 517 (ACTUAL)
- **Last updated:** 2023-01-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03196986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03196986, "mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03196986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*